Search

Your search keyword '"Tomita, Kichinobu"' showing total 92 results
Start Over Author "Tomita, Kichinobu"
92 results on '"Tomita, Kichinobu"'

8. Adjuvant chemotherapy with S-1 after curative chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck: Reanalysis of the ACTS-HNC study.

Author

Kubota, Akira, Nakatani, Eiji, Tsukahara, Kiyoaki, Hasegawa, Yasuhisa, Takemura, Hideki, Terada, Tomonori, Taguchi, Takahide, Nagahara, Kunihiko, Nakatani, Hiroaki, Yoshino, Kunitoshi, Higaki, Yuichiro, Iwae, Shigemichi, Beppu, Takeshi, Hanamure, Yutaka, Tomita, Kichinobu, Kohno, Naoyuki, Kawabata, Kazuyoshi, Teramukai, Satoshi, Fujii, Masato, and null, null

Subjects
HEAD & neck cancer treatment, CANCER treatment, SQUAMOUS cell carcinoma, ADJUVANT treatment of cancer, CANCER chemotherapy, CLINICAL trials
Abstract

Background: Chemoradiotherapy (CRT) has improved organ preservation or overall survival (OS) of locoregionally advanced head and neck squamous cell cancer (LAHNSCC), but in clinical trials of conventional CRT, increasing CRT intensity has not been shown to improve OS. In the Adjuvant ChemoTherapy with S-1 after curative treatment in patients with Head and Neck Cancer (ACTS-HNC) phase III study, OS of curative locoregional treatments improved more with adjuvant chemotherapy with S-1 (tegafur gimeracil oteracil potassium) than with tegafur/uracil (UFT). ACTS HNC study showed the significant efficacy of S-1 after curative radiotherapy in sub-analysis. We explored the efficacy of S-1 after curative CRT in a subset of patients from the ACTS-HNC study. Methods: Patients with stage III, IVA, or IVB LAHNSCC were enrolled in this study to evaluate the efficacy of S-1 compared with UFT as adjuvant chemotherapy after curative CRT in the ACTS-HNC study. Patients received S-1 at 80–120 mg/day in two divided doses for 2 weeks, followed by a 1-week rest, or UFT 300 or 400 mg/day in two or three divided doses daily, for 1 year. The endpoints were OS, disease-free survival, locoregional relapse-free survival, distant metastasis-free survival (DMFS), and post-locoregional relapse survival. Results: One hundred eighty patients (S-1, n = 87; UFT, n = 93) were included in this study. Clinical characteristics of the S-1 and UFT arms were similar. S-1 after CRT significantly improved OS (hazard ratio [HR], 0.46; 95% confidence interval [CI], 0.22–0.93) and DMFS (HR, 0.50; 95% CI, 0.26–0.97) compared with UFT. Conclusion: As adjuvant chemotherapy, S-1 demonstrated better efficacy for OS and DMFS than UFT in patients with LAHNSCC after curative CRT and may be considered a treatment option following curative CRT. For this study was not preplanned in the ACTS-HNC study, the results is hypothesis generating but not definitive. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

28. STANDARDIZING THE EXTENT FOR RESECTION OF THE CERVICAL LYMPH NODES AND NON-LYMPHATIC STRUCTURES IN NECK DISSECTIONS

Author

SAIKAWA, Masahisa, primary, KISHIMOTO, Seiji, additional, NAKASHIMA, Tadashi, additional, HASEGAWA, Yasuhisa, additional, SAIJO, Shigeru, additional, KAWABATA, Kazuyoshi, additional, YOSHIZUMI, Takashi, additional, NISHIJIMA, Wataru, additional, NIBU, ichi, additional, KOHNO, Naoyuki, additional, OHYAMA, Waichiro, additional, FUJII, Takashi, additional, TOMITA, Kichinobu, additional, ASAI, Masao, additional, SUGASAWA, Masashi, additional, FUJII, Masato, additional, NAKATANI, Hiroaki, additional, HAYASAKI, Katsutake, additional, ASAKAGE, Takahiro, additional, MONDEN, Nobuya, additional, ONITSUKA, Tetsuro, additional, TAKAGITA, Shinichi, additional, MIYAZAKI, Masakazu, additional, FURUKAWA, Madoka, additional, and OJIRI, Hiroya, additional

Published
2006
Full Text
View/download PDF

29. A NEW CLASSIFICATION AND NOMENCLATURE SYSTEM FOR NECK DISSECTIONS: A PROPOSAL BY THE JAPAN NECK DISSECTION STUDY GROUP (JNDSG).

Author

HASEGAWA, Yasuhisa, primary, SAIKAWA, Masahisa, additional, HAYASAKI, Katsutake, additional, SUGASAWA, Masashi, additional, KISHIMOTO, Seiji, additional, NAKASHIMA, Tadashi, additional, SAIJO, Shigeru, additional, KAWABATA, Kazuyoshi, additional, YOSHIZUMI, Takashi, additional, NISHIJIMA, Wataru, additional, OHYAMA, Waichiro, additional, TOMITA, Kichinobu, additional, NIBU, Ken-ichi, additional, FUJII, Takashi, additional, KOHNO, Naoyuki, additional, FUJII, Masato, additional, ASAI, Masao, additional, NAKATANI, Hiroaki, additional, TAKAGITA, Shin-ichi, additional, MONDEN, Nobuya, additional, ONITSUKA, Tetsuro, additional, ASAKAGE, Takahiro, additional, and MIYAZAKI, Masakazu, additional

Published
2005
Full Text
View/download PDF

38. SCCA1 expression in T-lymphocytes peripheral to cancer cells is associated with the elevation of serum SCC antigen in squamous cell carcinoma of the tongue

Author

Yasumatsu, Ryuji, primary, Nakashima, Torahiko, additional, Azuma, Kaoru, additional, Hirakawa, Naoya, additional, Kuratomi, Yuichiro, additional, Tomita, Kichinobu, additional, Cataltepe, Sule, additional, Silverman, Gary A, additional, Clayman, Gary L, additional, and Komiyama, Sohtaro, additional

Published
2001
Full Text
View/download PDF

43. Randomized Phase III Trial of Adjuvant Chemotherapy with S-1 after Curative Treatment in Patients with Squamous-Cell Carcinoma of the Head and Neck (ACTS-HNC).

Author

Tsukahara, Kiyoaki, Kubota, Akira, Hasegawa, Yasuhisa, Takemura, Hideki, Terada, Tomonori, Taguchi, Takahide, Nagahara, Kunihiko, Nakatani, Hiroaki, Yoshino, Kunitoshi, Higaki, Yuichiro, Iwae, Shigemichi, Beppu, Takeshi, Hanamure, Yutaka, Tomita, Kichinobu, Kohno, Naoyuki, Kawabata, Kazuyoshi, Fukushima, Masanori, Teramukai, Satoshi, Fujii, Masato, and null, null

Subjects
SQUAMOUS cell carcinoma, HEAD & neck cancer treatment, ADJUVANT treatment of cancer, CANCER chemotherapy, CLINICAL trials, ADVERSE health care events, PATIENTS
Abstract

Background: We conducted a phase III study to evaluate S-1 as compared with UFT as control in patients after curative therapy for stage III, IVA, or IVB squamous-cell carcinoma of the head and neck (SCCHN). Patients and Methods: Patients were randomly assigned to the UFT group (300 or 400 mg day-1 for 1 year) or the S-1 group (80, 100, or 120 mg day-1 for 1 year). The primary end point was disease-free survival (DFS). Secondary end points were relapse-free survival, overall survival (OS), and safety. Results: A total of 526 patients were enrolled, and 505 were eligible for analysis. The 3-year DFS rate was 60.0% in the UFT group and 64.1% in the S-1 group (HR, 0.87; 95%CI, 0.66-1.16; p = 0.34). The 3-year OS rate was 75.8% and 82.9%, respectively (HR, 0.64; 95% CI, 0.44-0.94; p = 0.022). Among grade 3 or higher adverse events, the incidences of leukopenia (5.2%), neutropenia (3.6%), thrombocytopenia (2.0%), and mucositis/stomatitis (2.4%) were significantly higher in the S-1 group. Conclusions: Although DFS did not differ significantly between the groups, OS was significantly better in the S-1 group than in the UFT group. S-1 is considered a treatment option after curative therapy for stage III, IVA, IVB SCCHN. Trial Registration: NCT00336947 [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

44. Clinical Analysis of Parotid Cancer.

Author

Yasumatsu, Ryuji, primary, Ichibangase, Takashi, additional, Tomita, Kazuhide, additional, Hara, Takashi, additional, Sueta, Takayuki, additional, Hirakawa, Naoya, additional, Higaki, Yuichiro, additional, and Tomita, Kichinobu, additional

Published
1999
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results